RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1016%2Fj.eclinm.2023.102372
https://w3id.org/ripe/ripe-kg/work/10.1016%2Fj.eclinm.2023.102372
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
prism:doi |
10.1016/j.eclinm.2023.102372 |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
dcterms:title |
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
rdf:type |
node1 |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |
owl:sameAs |
https://semopenalex.org/work/W4389695243 |
ripekg:work/10.1016%2Fj.nmni.2025.101692Homologous and heterologous booster of COVID-19 vaccines: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fj.eclinm.2023.102372Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos) |